Patent EstateWe aim to establish what we believe is and will be a strong position in intellectual property relevant to our Adnectin™ class and Adnectin-based products, PROfusion™ for engineering biologics, and our initial product candidate, Angiocept™. Our patent estate includes over 100 patents and patent applications. |